Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Kinase targets in CNS drug discovery

    Access Status
    Fulltext not available
    Authors
    Gunosewoyo, Hendra
    Yu, L.
    Munoz, L.
    Kassiou, M.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Gunosewoyo, H. and Yu, L. and Munoz, L. and Kassiou, M. 2017. Kinase targets in CNS drug discovery. Future Medicinal Chemistry. 9 (3): pp. 303-314.
    Source Title
    Future Medicinal Chemistry
    DOI
    10.4155/fmc-2016-0214
    ISSN
    1756-8927
    School
    School of Pharmacy
    URI
    http://hdl.handle.net/20.500.11937/50188
    Collection
    • Curtin Research Publications
    Abstract

    Originally thought to be nondruggable, kinases represent attractive drug targets for pharmaceutical companies and academia. To date, there are over 40 kinase inhibitors approved by the US FDA, with 32 of these being small molecules, in addition to the three mammalian target of rapamycin inhibitor macrolides (sirolimus, temsirolimus and everolimus). Despite the rapid development of kinase inhibitors for cancer, presently none of these agents are approved for CNS indications. This mini perspective highlights selected kinase targets for CNS disorders, of which brain-permeable small-molecule inhibitors are reported, with demonstrated preclinical proof-of-concept efficacy. This is followed by a brief discussion on the key challenges of blood-brain barrier penetration and selectivity profiles in developing kinase inhibitors for CNS disorders.

    Related items

    Showing items related by title, author, creator and subject.

    • PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
      Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, Pieter ; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; Gili, M.; Russillo, M.; Parra, J.L.; Singh, S.; Arribas, J.; Rosen, N.; Baselga, J. (2011)
      There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since it is highly deregulated in this disease ...
    • A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
      Falasca, Marco; Chiozzotto, D.; Godage, H.; Mazzoletti, M.; Riley, A.; Previdi, S.; Potter, B.; Broggini, M.; Maffucci, T. (2010)
      Background: Owing to its role in cancer, the phosphoinositide 3-kinase (PI3K)/Akt pathway is an attractive target for therapeutic intervention. We previously reported that the inhibition of Akt by inositol 1,3,4,5,6- ...
    • Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27
      Mellier, G.; Liu, D.; Bellot, G.; Lisa Holme, A.; Pervaiz, Shazib (2013)
      The small chaperone protein Hsp27 confers resistance to apoptosis, and therefore is an attractive anticancer drug target. We report here a novel mechanism underlying the tumor necrosis factor-related apoptosis-inducing ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.